|
1
|
Gajjar A, Chintagumpala M, Ashey D, Kellie
S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, et
al: Risk-adapted craniospinal radiotherapy followed by high-dose
chemotherapy and stem-cell rescue in children with newly diagnosed
medulloblastoma (St Jude Medulloblastoma-96): Ong-term results from
a prospective, multicentre trial. Lancet Oncol. 7:813–820. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Packer RJ: Risk-adapted craniospinal
radiotherapy followed by high-dose chemotherapy and stem-cell
rescue in children with newly diagnosed medulloblastoma. Curr
Neurol Neurosci Rep. 7:130–132. 2007.
|
|
3
|
Aref D and Croul S: Medulloblastoma:
Recurrence and metastasis. CNS Oncol. 2:377–385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Horten BC and Rubinstein LJ: Primary
cerebral neuroblastoma. A clinicopathological study of 35 cases.
Brain. 99:735–756. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mazloom A, Zangeneh AH, Teh BS and Paulino
AC: Extraneural metastasis of medulloblastoma. J Clin Oncol.
27:20652009.
|
|
6
|
Elabd S, Meroni G and Blattner C: TRIMming
p53's anticancer activity. Oncogene. 35:5577–5584. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lazzari E and Meroni G: TRIM32 ubiquitin
E3 ligase, one enzyme for several pathologies: From muscular
dystrophy to tumours. Int J Biochem Cell Biol. 79:469–477. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Thé H, Lavau C, Marchio A, Chomienne C,
Degos L and Dejean A: The PML-RAR alpha fusion mRNA generated by
the t(15;17) translocation in acute promyelocytic leukemia encodes
a functionally altered RAR. Cell. 66:675–684. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cambiaghi V, Giuliani V, Lombardi S,
Marinelli C, Toffalorio F and Pelicci PG: TRIM proteins in cancer.
Adv Exp Med Biol. 770:77–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Le Douarin B, Zechel C, Garnier JM, Lutz
Y, Tora L, Pierrat P, Heery D, Gronemeyer H, Chambon P and Losson
R: The N-terminal part of TIF1, a putative mediator of the
ligand-dependent activation function (AF-2) of nuclear receptors,
is fused to B-raf in the oncogenic protein T18. EMBO J.
14:2020–2033. 1995.PubMed/NCBI
|
|
12
|
Licchesi JD, Van Neste L, Tiwari VK, Cope
L, Lin X, Baylin SB and Herman JG: Transcriptional regulation of
Wnt inhibitory factor-1 by Miz-1/c-Myc. Oncogene. 29:5923–5934.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Valiyeva F, Jiang F, Elmaadawi A, Moussa
M, Yee SP, Raptis L, Izawa JI, Yang BB, Greenberg NM, Wang F and
Xuan JW: Characterization of the oncogenic activity of the novel
TRIM59 gene in mouse cancer models. Mol Cancer Ther. 10:1229–1240.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou Z, Ji Z, Wang Y, Li J, Cao H, Zhu HH
and Gao WQ: TRIM59 is up-regulated in gastric tumors, promoting
ubiquitination and degradation of p53. Gastroenterology.
147:1043–1054. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Khatamianfar V, Valiyeva F, Rennie PS, Lu
WY, Yang BB, Bauman GS, Moussa M and Xuan JW: TRIM59, a novel
multiple cancer biomarker for immunohistochemical detection of
tumorigenesis. BMJ Open. 2:pii: e001410. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhan W, Han T, Zhang C, Xie C, Gan M, Deng
K, Fu M and Wang JB: TRIM59 promotes the proliferation and
migration of non-small cell lung cancer cells by upregulating cell
cycle related proteins. PLoS One. 10:e1425962015. View Article : Google Scholar
|
|
17
|
Liang J, Xing D, Li Z, Shen J, Zhao H and
Li S: TRIM59 is upregulated and promotes cell proliferation and
migration in human osteosarcoma. Mol Med Rep. 13:5200–5206. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aierken G, Seyiti A, Alifu M and Kuerban
G: Knockdown of tripartrtite-59 (TRIM59) inhibits cellular
proliferation and migration in human cervical cancer cells. Oncol
Res. 25:381–388. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin WY, Wang H, Song X, Zhang SX, Zhou PS,
Sun JM and Li JS: Knockdown of tripartite motif 59 (TRIM59)
inhibits tumor growth in prostate cancer. Eur Rev Med Pharmacol
Sci. 20:4864–4873. 2016.PubMed/NCBI
|
|
20
|
Li LL, Xue AM, Li BX, Shen YW, Li YH, Luo
CL, Zhang MC, Jiang JQ, Xu ZD, Xie JH and Zhao ZQ: JMJD2A
contributes to breast cancer progression through transcriptional
repression of the tumor suppressor ARHI. Breast Cancer Res.
16:R562014. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Valastyan S and Weinberg RA: Tumor
metastasis: Molecular insights and evolving paradigms. Cell.
147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Strauss R, Li ZY, Liu Y, Beyer I, Persson
J, Sova P, Möller T, Pesonen S, Hemminki A, Hamerlik P, et al:
Analysis of epithelial and mesenchymal markers in ovarian cancer
reveals phenotypic heterogeneity and plasticity. PLoS One.
6:e161862011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shenoy AK, Jin Y, Luo H, Tang M, Pampo C,
Shao R, Siemann DW, Wu L, Heldermon CD, Law BK, et al:
Epithelial-to-mesenchymal transition confers pericyte properties on
cancer cells. J Clin Invest. 126:4174–4186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abdullah LN and Chow EK: Mechanisms of
chemoresistance in cancer stem cells. Clin Transl Med. 2:32013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Iwatsuki M, Mimori K, Yokobori T, Ishi H,
Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal
transition in cancer development and its clinical significance.
Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Phiboonchaiyanan PP, Busaranon K,
Ninsontia C and Chanvorachote P: Benzophenone-3 increases
metastasis potential in lung cancer cells via epithelial to
mesenchymal transition. Cell Biol Toxicol. 33:251–261. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hartmann W, Digon-Söntgerath B, Koch A,
Waha A, Endl E, Dani I, Denkhaus D, Goodyer CG, Sörensen N,
Wiestler OD and Pietsch T: Phosphatidylinositol 3′-kinase/AKT
signaling is activated in medulloblastoma cell proliferation and is
associated with reduced expression of PTEN. Clin Cancer Res.
12:3019–3027. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baryawno N, Sveinbjörnsson B, Eksborg S,
Chen CS, Kogner P and Johnsen JI: Small-molecule inhibitors of
phosphatidylinositol 3-kinase/Akt signaling inhibit
Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma
growth. Cancer Res. 70:266–276. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guerreiro AS, Fattet S, Fischer B, Shalaby
T, Jackson SP, Schoenwaelder SM, Grotzer MA, Delattre O and Arcaro
A: Targeting the PI3K p110alpha isoform inhibits medulloblastoma
proliferation, chemoresistance, and migration. Clin Cancer Res.
14:6761–6769. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ehrhardt M, Craveiro RB, Holst MI, Pietsch
T and Dilloo D: The PI3K inhibitor GDC-0941 displays promising in
vitro and in vivo efficacy for targeted medulloblastoma therapy.
Oncotarget. 6:802–813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang F, Li M, Wu X, Hu Y, Cao Y, Wang X,
Xiang S, Li H, Jiang L, Tan Z, et al: 20(S)-ginsenoside Rg3
promotes senescence and apoptosis in gallbladder cancer cells via
the p53 pathway. Drug Des Devel Ther. 9:3969–3987. 2015.PubMed/NCBI
|
